In May, FDA approved Voquenza (vonoprazan fumarate), in combination with anti-biotics, for H.pylori infection. In March, Phathom Pharmaceuticals submitted an NDA to FDA for the use of vonoprazan as a treatment for the healing of all grades of erosive reflux esophagitis and relief of heartburn.
New GI Treatment Voquenza Approved For Helicobacter Pylori Infection; Other Indications May Follow
